VADP_BAA_Amendment2.pdf

Amendment #2 to BAA-NIAID-75N93022R00022

VACCINE ADJUVANT DISCOVERY PROGRAM

Amendment to Solicitation No.:

BAA-NIAID-75N93022R00022

Amendment No.: 2

Issue Date: March 31, 2023

Effective Date:

Proposal Due Date:

March 31, 2023

May 30, 2023 until 3:00 pm EST (UNCHANGED)

Issued By: Maribel Miranda Contracting Officer

NIH/NIAID

Office of Acquisitions 5601 Fishers Lane Room 3C20 MSC 9821 Rockville, MD 20852

Point of Contact: Maribel Miranda, Contracting Officer Maribel.Miranda@nih.gov

Name and Address of Offeror: To All Potential Offerors

The above numbered solicitation is amended as set forth below. The hour and date specified for receipt of proposals has NOT changed. Offerors must acknowledge receipt of this amendment. Failure to receive your acknowledgement of this amendment may result in the rejection of your offer.

NOTE: As part of this Amendment, we request that all questions pertaining to the BAA be submitted to the Government no later than April 19, 2023, 3:00pm EST.

The purpose of this amendment is to update SECTION L of the solicitation document and to provide responses to questions which may be useful to all potential offerors.

SECTION 1- ADMINISTRATIVE

SECTION L - INSTRUCTIONS, CONDITIONS, AND NOTICES TO OFFERORS, 2. INSTRUCTIONS TO OFFERORS,

c. BUSINESS PROPOSAL INSTRUCTIONS, is hereby modified as follows:

7. Small Business Subcontracting Plan

If the proposed contract exceeds a total estimated cost of $750,000 for the entire period of performance, the offeror shall be required to submit an acceptable subcontracting plan in accordance with the terms of the clause entitled "Small Business Subcontracting Plan," FAR Clause No. 52.219-9, incorporated herein by reference in the Solicitation, See SECTION J - LIST OF ATTACHMENTS, BUSINESS PROPOSAL ATTACHMENTS of this BAA for an example of such a plan…

SECTION 2- QUESTIONS AND RESPONSES

This section of the amendment provides questions submitted by potential applicants/offerors and the responses provided by NIAID. The responses are offered for information only and do not modify or become part of this solicitation. This Amendment will be updated as needed to add further questions and their related responses. All potential offerors are advised to refer back to all previous amendments for additional questions and clarification.

Question 1: For the required Hight-Throughput Screening (under Activity 1), is the number of compound libraries that can be used for the HTS limited and how do I know whether a particular library had previously been used by an awardee from the NIAID Adjuvant Discovery Program?

Response to Question 1: There are no restrictions in terms of the number of compound libraries that can be used and decision should be based on the number of compounds in the library/libraries and the number of compounds the offeror can reasonably screen. The offeror should also describe the rationale for selecting specific libraries.

Since different offerors use different readouts and focus on different target receptors or pathways, it is likely that they will identify non-overlapping hits in the same libraries.